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Abstract: A shift in glucose metabolism from oxidative phosphorylation to glycolysis is 
one of the biochemical hallmarks of tumor cells. Mitochondrial defects have been 
proposed to play an important role in the initiation and/or progression of various types of 
cancer. In the past decade, a wide spectrum of mutations and depletion of mtDNA have 
been identified in human cancers. Moreover, it has been demonstrated that activation of 
oncogenes or mutation of tumor suppressor genes, such as p53, can lead to the 
upregulation of glycolytic enzymes or inhibition of the biogenesis or assembly of 
respiratory enzyme complexes such as cytochrome c oxidase. These findings may explain, 
at least in part, the well documented phenomena of elevated glucose uptake and 
mitochondrial defects in cancers. In this article, we review the somatic mtDNA 
alterations with clinicopathological correlations in human cancers, and their potential 
roles in tumorigenesis, cancer progression, and metastasis. The signaling pathways 
involved in the shift from aerobic metabolism to glycolysis in human cancers are  
also discussed. 
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1. Introduction 
  
Mitochondria are cytoplasmic organelles that play a variety of important roles, including the 
generation of ATP through  respiration and  oxidative phosphorylation (OXPHOS), production of 
reactive oxygen species (ROS), and initiation and execution of apoptosis [1]. Compared with 
glycolysis, mitochondrial respiration and OXPHOS is a more efficient pathway to generate ATP from 
glucose in normal human cells. In contrast, a shift in glucose metabolism from OXPHOS to glycolysis 
has been frequently observed in cancer cells and represents an important biochemical hallmark  
of tumors. 
As early as 1930, the German biochemist Otto Warburg first proposed that tumor cells, unlike 
normal cells, exhibit an increased utilization of glycolytic pathway for energy production, even when 
there is abundant oxygen for mitochondria to make ATP via respiration and OXPHOS [2]. This 
phenomenon is known as the Warburg effect. He further proposed that defects in energy metabolism, 
specifically in mitochondria, may play an important role in the initiation or progression of cancers [3]. 
Based on the fact that glucose uptake is increased in cancer cells, the positron emission tomography 
(PET) of 
19F-glucose in affected tissues has been widely used in clinical diagnosis of cancers. However, 
the molecular and cellular mechanisms of the Warburg effect and its roles in cancer biology have not 
been fully elucidated. 
Human mitochondrial DNA (mtDNA) is a 16,569 bp double-stranded circular DNA molecule, and 
several hundred to several thousand copies of mtDNA are present in each cell. The human mtDNA 
encodes 13 polypeptides, which are essential constituents of respiratory enzyme complexes, and 22 
transfer RNAs and two ribosomal RNAs that are required for protein synthesis in mitochondria [4]. 
Mammalian mtDNA is more susceptible to oxidative damage and has a higher mutation rate compared 
with nuclear DNA due to a lack of protective histone proteins, limited DNA repair activities, and a 
high rate of generation of ROS in mitochondria [5]. Somatic mutation and damage to mtDNA can 
result in impairment of the OXPHOS system and enhanced ROS production, which in turn accelerates Int. J. Mol. Sci. 2009, 10                 
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the rate of DNA mutation. This scenario has been proposed to be involved in the initiation of 
carcinogenesis [6]. 
One of the hypotheses, which may explain the Warburg effect, is that cancer cells accumulate 
mtDNA alterations and lead to defects in mitochondrial respiration and ATP generation by the 
OXPHOS system [7,8]. It has been established that some of the acquired mtDNA mutations can impair 
the function of OXPHOS, increase the production of ROS and thereby promote tumor cell 
proliferation. The other acquired mutations of mtDNA may confer tumor cells with the ability to adapt 
to the new microenvironment or cope with stress during progression and metastasis of the tumor. 
In this article, we review recent findings of somatic mtDNA alterations and mitochondrial 
dysfunction in human cancers. Moreover, we examine the roles of mutation and depletion of mtDNA 
in the pathophysiology, initiation and progression of cancers. The signaling pathways that may be 
involved in the shift of aerobic metabolism to glycolysis in cancer cells are also discussed. 
 
2. Somatic mtDNA alterations in human cancers 
 
In the past decade, various types of mtDNA alterations have been identified in primary human 
cancers. These mtDNA alterations include point mutations, deletions, insertions, tandem duplications, 
and copy number changes. 
 
2.1. Point mutations 
 
Polyak et al. [9] first reported that somatic point mutations of mitochondrial genome occurred in 
human colorectal tumors. In this study, the entire mtDNAs of 10 human colorectal cancer cell lines 
were completely sequenced and seven were found to carry mutations in protein coding genes or rRNA 
genes. Importantly, the study further revealed that most of the mtDNA mutations were homoplasmic. 
On the basis of these findings, the authors suggested that mitochondria could rapidly become 
homogeneous in colorectal cancer cells. Moreover, some of these point mutations identified within 
protein-coding regions could lead to frame-shift or amino acid substitutions. 
Fliss et al. [10] reported that 64% (9/14) of bladder cancers, 46% (6/13) of head and neck cancers, 
and 43% (6/14) of lung cancers harbored point mutations of mtDNA. It was confirmed that the 
majority of these somatic mutations of mtDNA were homoplasmic. In addition to mutations in the 
coding region of mtDNA, a high frequency of somatic mutation was located in the non-coding 
displacement loop (D-loop) region of mtDNA. 
Table 1 summarizes the results of recent studies on primary tumors [9-25]. The data clearly indicate 
that high frequencies of somatic mutations of mtDNA occur in various types of cancers, and that many 
of the mtDNA mutations are located in the D-loop region of mtDNA. A number of extensive analysis 
of somatic mutation in the D-loop region of mtDNA revealed that base insertions or deletions at 
nucleotide position (np) 303-309, a polycytidine stretch (C-tract) termed D310, are the most common Int. J. Mol. Sci. 2009, 10                 
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mutations of mtDNA in human cancers (Table 2) [10-16,18,19,21-23,25-46]. Some of the D310 
variations have also been reported as common variants in normal human tissues [47]. 
 
Table 1. Somatic mutations in mtDNA of human cancers. 
Cancer type 
and case number 
Somatic mutations in mtDNA of cancers 
Reference  Frequency 
(%) 
% of mutations in the 
D-loop region 
% of mutations in 
coding regions 
Bladder cancer         
N = 14  64  30  70  [10] 
Brain tumor         
N = 15  40  61  39  [11] 
Breast cancer         
N = 18  61  58  42  [12] 
N = 19  74  81.5  18.5  [13] 
N = 15  93  38  62  [14] 
Colorectal cancer         
N = 10  70  0  100  [9] 
Head & neck cancer         
N = 13  46  67  33  [10] 
N = 83  49  25  75  [15] 
Lung cancer         
N = 14  43  70  30  [10] 
N = 55  60  32  68  [16] 
Nasopharyngeal cancer       
N = 23  52  92  8  [17] 
Oral cancer         
N = 18  78  77  23  [18] 
Ovarian cancer         
N = 10  60  73  27  [19] 
Pancreatic cancer         
N = 5  80  0  100  [20] 
Renal cancer         
N = 8  62.5  17  83  [21] 
N = 9  78  33  67  [22] 
N = 15  47  29  71  [23] 
Thyroid cancer         
N = 13  23  0  100  [24] 
N = 66  68  51  49  [25] 
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Table 2. Somatic mutations in the D-loop region of mtDNA of human cancers. 
Cancer type 
and case number 
Somatic mutations in the D-loop of mtDNA 
Reference 
Frequency (%)  % of mutations in D310   
Bladder cancer         
N = 14  36  17    [10] 
Brain tumor         
N = 15  40  45.5    [11] 
Breast cancer         
N = 18  39  71    [12] 
N = 19  63  18    [13] 
N = 15  53  29    [14] 
N = 60  30  72    [26] 
N = 59  42  45    [27] 
Colorectal cancer         
N = 13  23  33    [28] 
N = 25  40  90    [29] 
Cutaneous neurofibromas         
N = 19  37  71    [30] 
Esophageal cancer         
N = 37  5  50    [31] 
N = 20  40  54    [32] 
N = 21  33  13    [33] 
Gastric cancer         
N = 8  37  25    [28] 
N = 45  4  0    [34] 
N = 31  48  67    [35] 
Head & neck cancer         
N = 13  23  17    [10] 
N = 109  21  76    [36] 
N = 83  29  0    [15] 
Hepatocellular carcinoma         
N = 19  68  61.5    [37] 
N = 50  34  42    [38] 
N = 61  39  41    [39] 
N = 18  22  100    [40] 
Lung cancer         
N = 14  36  14    [10] 
N = 202  17  0    [41] 
N = 31  23  57    [29] 
N = 55  31  22    [16] 
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Table 2. Cont. 
Cancer type 
and case number 
Somatic mutations in the D-loop of mtDNA 
Reference 
Frequency (%)  % of mutations in D310   
Oral cancer         
N = 30  57  22    [42] 
N = 18  67  40    [18] 
Ovarian cancer         
N = 10  50  18    [19] 
N = 35  26  10    [43] 
N = 44  57  45.5    [44] 
Plexiform neurofibromas         
N = 18  50  18.5    [30] 
Prostate cancer         
N = 16  87.5  16.7    [45] 
N = 10  50  50    [46] 
Renal cancer         
N = 8  12.5  0    [21] 
N = 9  33  0    [22] 
N = 15  27  0    [23] 
Thyroid cancer         
N = 66  48.5  36    [25] 
 
An in vitro analysis revealed that the D-loop, and especially the D310 region, is more susceptible to 
oxidative damage and electrophilic attack as compared with other regions of mtDNA [48]. In addition 
to a high susceptibility to DNA damage and mutation, an inefficient DNA repair system in 
mitochondria has been suggested to contribute to the high frequency of homoplasmic D310 C-tract 
frame-shift mutations in many types of cancers [48]. Extensive oxidative damage to the poly C repeat 
may result in slipping and/or mis-incorporation during replication or repair of mtDNA by 
mitochondrial DNA polymerase γ, and in turn lead to mtDNA mutations in cancer cells. In many 
human cancers the decrease in the replication and DNA repair activities of DNA polymerase γ could 
contribute to the extremely high incidence of mutation in the D-loop of mtDNA [49,50]. 
 
2.2. Deletions 
 
Large-scale deletions of mtDNA have been detected in various types of cancers (Table 3) [25-27, 33, 
35, 39, 40, 51-68]. The 4,977 bp deletion is one of the common mtDNA mutations detected in aging 
human tissues [69]. This deletion has 13-bp direct repeats flanking the 5’- and 3’-end breakpoints at np 
8470/8482 and np 13447/13459, respectively. We first reported that this 4,977 bp deletion was largely 
accumulated in sun-exposed skin tissues and also occurred in the squamous cell carcinomas and 
precancerous skin tissues [63]. The 4,977 bp deletion of mtDNA was later detected in oral cancers and Int. J. Mol. Sci. 2009, 10                 
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paired non-malignant oral tissues of patients with betel quid chewing history [60]. Although the 4,977 
bp deletion of mtDNA has been frequently detected in various types of cancers (Table 3), the incidence 
and amount of the 4,977 bp-deleted mtDNA are significantly lower in the malignant tissues as 
compared with the paired normal tissues of cancer patients. We have suggested that during cancer 
progression the mtDNA with a deletion is decreased (diluted) as a result of clonal expansion of cell 
lineages that contain less or no mtDNA deletion. A study of micro-dissected tumor tissues further 
confirmed the lower incidence of 4977 bp mtDNA deletion in most tumors [51]. On the other hand, an 
increase in large-scale deletions of mtDNA was found in radiation-associated thyroid tumors [66]. 
 
Table 3. MtDNA deletions in human cancers. 
Deletions 
Nucleotide 
position 
Cancer types  Reference 
4977 bp 
8470-13447 or 
8482-13459 
Breast cancer  [26,51,52] 
   Endometrial  cancer  [53] 
   Esophageal  cancer  [33] 
   Gastric  cancer  [35,51,54] 
    Head and neck cancer  [51,55] 
   Hepatocellular  carcinoma  [40,56-58] 
   Lung  cancer  [59] 
   Oral  cancer  [60,61] 
    Renal cell carcinoma  [62] 
   Skin  cancer  [63-65] 
   Thyroid  cancer [25,62,66] 
      
50 bp  298-348 or 306-356  Gastric cancer  [67] 
   Hepatocellular  carcinoma  [39] 
      
294 bp  3323-3588  Renal cell carcinoma  [68] 
 
A 50-bp deletion flanked by a 9-bp direct repeat in the D-loop region of mtDNA was identified in 
the tumor tissues of four patients with gastric cancer [67] and in one patient with hepatocellular 
carcinoma (HCC) [39]. The mtDNA deletion appeared to be homoplasmic and was largely 
accumulated in tumors, but not detected in paired normal tissues. In addition, a 294-bp deletion in the 
ND1 gene of mtDNA was detected in a patient with renal cell carcinoma [68]. Approximately 50% of 
the mtDNA molecules in the primary renal cell carcinoma contained this deletion, but none of the 
metastatic sites and unaffected tissues had this deletion in the ND1 gene. Taken together, these 
observations indicate that mtDNA deletions of different sizes occur and distribute in a stochastic Int. J. Mol. Sci. 2009, 10                 
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manner in cancer tissues and tend to become more homogeneous, as a result of clonal expansion, 
during the progression of tumors. 
 
2.3. Insertions 
 
We identified two small insertions (~260 bp and ~520 bp) in the D-loop region of mtDNA in the 
cancerous tissues of one patient with gastric cancer [35]. The two insertions were characterized as 
tandem duplication and tandem triplication and the replicated DNA sequence is approximately 260-bp 
in size and is flanked by two poly-C stretches at np 303-309 and np 568-573, respectively. Such 
tandem duplications in the D-loop of mtDNA have also been detected in patients with mitochondrial 
myopathy [70-72], in somatic tissues of elderly subjects [73, 74], and in a Caucasian population with a 
specific mtDNA haplogroup [47]. In a further survey using a more sensitive molecular biological 
technique, we detected tandem duplication or triplication of mtDNA in approximately 5% of the 
patients with different types of cancers [75]. Moreover, it was found that the occurrence of the tandem 
duplications or triplications was highly associated with the presence of length variation at np 568 of 
the poly-C stretch in the D-loop of mtDNA [75]. Because the tandem duplication or triplication was 
also detected in the non-cancerous tissues of cancer patients and in about 4% of peripheral blood cells 
of normal subjects, we contend that the occurrence of tandem duplication or triplication in the D-loop 
region of mtDNA is not specific to cancers [75]. It was suggested that this type of mtDNA mutation is 
associated with the instability in the number of Cs starting at np 568 in the D-loop of mtDNA [75]. 
 
2.4. Copy number changes 
 
Alterations in the copy number of mtDNA in cancer have been frequently found in various human 
cancers (Table 4) [26, 27, 29, 35, 39, 76-81]. A decrease in the content of mtDNA in cancer tissues has 
been reported in most of renal carcinomas [78, 79, 82], HCCs [39, 40, 77, 83], gastric cancers [35], 
and breast cancers [26, 27, 76]. However, an increase in the copy number of mtDNA was found in the 
majority of renal oncocytomas [78, 82], salivary gland oncocytomas [82], head and neck cancers [84], 
papillary thyroid carcinomas [76], colorectal cancers [29, 80], endometrial cancers [85], ovarian cancer 
[86], and prostate cancers [80]. These findings suggest that a change in the content of mtDNA is 
related to the type of cancers. 
It was demonstrated that the decrease in mtDNA copy number is associated with the point 
mutations located near the replication origins in the D-loop of mtDNA in HCCs [39] and breast 
cancers [27]. In addition, it was revealed that altered mRNA expression of the genes involved in 
mitochondrial biogenesis, such as peroxisome proliferator-activated receptor γ coactivator-1α 
(PGC-1α) and mitochondrial single strand DNA binding protein (mtSSB) may be related to or 
responsible for the decrease in mtDNA copy number in HCCs [40]. These results suggest that somatic 
mutations in the D-loop of mtDNA and impairment in mitochondrial biogenesis may contribute to the 
decrease of mtDNA copy number in human cancers [29]. Int. J. Mol. Sci. 2009, 10                 
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Table 4. Alterations in mtDNA content of human cancers. 
Cancer type  Alterations in mtDNA content  Reference 
Case number  Increase or Decrease  Frequency (%)     
Breast cancer         
N = 25  Decrease  80    [76] 
N = 60  Decrease  63    [26] 
N = 59  Decrease  78    [27] 
Gastric cancer         
N = 31  Decrease  55    [35] 
Hepatocellular carcinoma         
N = 38  Decrease  61    [39] 
N = 31  Decrease  77    [77] 
Renal cancer         
N = 13  Decrease  61    [78] 
N = 37  Decrease  91    [79] 
Colorectal cancer         
N = 25  Increase  40    [29] 
N = 153  Increase  39    [80] 
Lung cancer         
N = 31  Increase  48    [29] 
Papillary thyroid cancer         
N = 20  Increase  65    [76] 
Prostate cancer         
N = 9  Increase  78    [81] 
 
On the other hand, the increase in mtDNA content in cancers could be related to an increase of 
oxidative stress. It was demonstrated that enhanced oxidative stress can induce increases in 
mitochondrial mass and the copy number of mtDNA [87]. Moreover, an increase in the content of 
mtDNA was found to associate with elevated oxidative stress in aging tissues and in late passages of 
diploid human skin fibroblasts [88, 89]. Therefore, an increase in oxidative stress could lead to the 
increase of mitochondrial mass and mtDNA content in human cancers. In addition, the increase of 
mtDNA copy number could be a result of the feedback response that compensates for mitochondria 
with impaired respiratory function or mtDNA mutation in human cells [89]. 
 
3. Clinical correlations of somatic mtDNA alterations in cancers 
 
3.1. Point mutations 
 
Matsuyama and coworkers [41] found that in 202 patients with non-small cell lung cancer 
examined, the average mutation rate in the D-loop of mtDNA of patients at stage IIIB or stage IV was Int. J. Mol. Sci. 2009, 10                 
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significantly higher than that of patients at lower clinical stages. Moreover, the stage IIIB or stage IV 
cancer patients carrying point mutations in the D-loop of mtDNA exhibited poorer prognosis compared 
with those free of the mtDNA mutations [41]. 
Tamori  et al. [89] observed a higher frequency of D-loop mutations of mtDNA in poorly 
differentiated HCCs. However, there was no relationship between the occurrence of D-loop mutations 
in mtDNA and the age of cancer patients or between mtDNA mutation and hepatitis virus  
infection [90]. 
A study of 365 colorectal cancer patients revealed that the presence of D-loop mutations is a factor 
of poor prognosis in patients with colorectal cancers [91]. In the subgroup of patients with stage III 
colon cancer receiving fluorouracil-based adjuvant chemotherapy, the three-year survival rate for 
patients with D-loop mutation of mtDNA was significantly lower than those without D-loop mutations 
[91]. It was suggested that D-loop mutations of mtDNA are related to the resistance to adjuvant 
chemotherapy in patients afflicted with stage III colon cancers.   
Recently, we analyzed the association between the clinicopathological features and D-loop 
mutations of mtDNA in 60 patients with breast cancers and found that the occurrence of D-loop 
mutations of mtDNA is associated with old onset age (≥ 50 years) and with the tumors that lacked the 
expressions of estrogen receptor and progesterone receptor, respectively [26]. Moreover, we noticed 
that the breast cancer patients harboring D-loop mutations of mtDNA had significantly poorer 
disease-free survival compared with those without mtDNA mutations [26]. These observations suggest 
that somatic mutation in the D-loop of mtDNA can be considered as a new prognostic marker for some 
types of cancers, and that mtDNA mutations may play a role in cancer progression and in response to 
anticancer drug treatment. 
In contrast, a study of 109 patients with head and neck cancers revealed that the presence of D-loop 
mutations of mtDNA was not associated with the prognosis or the response of patients to neoadjuvant 
chemotherapy [36]. Moreover, no significant association was found between somatic mtDNA 
mutations and clinicopathological characteristics in esophageal cancer [31, 92], gastric cancer [35], 
lung cancer [16], and ovarian cancer [44], respectively. 
 
3.2. Copy number changes 
 
Yin et al. [40] reported that the copy number of mtDNA was frequently reduced in HCCs. Moreover, 
reduction in the copy number of mtDNA was more frequently observed in female patients with HCCs 
as compared with male patients with HCCs. This finding suggests that the differential alterations in the 
mtDNA copy number of cancer tissues of male and female patients may contribute to the differences in 
clinical manifestation, progression, and mortality rate between male and female HCC patients [40]. 
Yamada  et al. [77] reported that mtDNA copy number was reduced in HCCs compared with the 
corresponding non-cancerous liver tissues, and that low mtDNA content of HCCs was significantly 
correlated with large tumor size and liver cirrhosis. Moreover, patients with lower mtDNA content in 
HCCs tended to show poorer 5-year survival compared with the patients with higher mtDNA content Int. J. Mol. Sci. 2009, 10                 
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in HCCs, which suggest that decrease in the mtDNA content may be associated with malignancy of 
HCCs [77]. 
In gastric cancers, we analyzed the association between the clinicopathological features and the 
mtDNA content and found that a decrease of mtDNA content is significantly associated with ulcerated 
and infiltrating type (Borrmann’s type III) and diffusely thick type (Borrmann’s type IV) of gastric 
carcinomas [35]. Most patients with types III and IV gastric cancers, respectively, were found to have 
poor prognosis and lower 5-year survival rate after gastric resection. These results suggest that the 
reduction in the content of mtDNA may contribute to the malignancy and progression of gastric 
cancers [35]. 
A decrease in mtDNA copy number was also found to associate with an older onset age (> 50 years 
old) and a higher histological grade of breast cancer [27]. In addition, patients with reduced mtDNA 
content had significantly poorer disease-free survival and overall survival rate [27]. These results 
suggest that reduction in the content of mtDNA may be involved in neoplastic transformation or 
progression of breast cancers. However, no similar association was found in other studies of breast 
cancer patients [26,76]. 
The mtDNA content in ovarian carcinomas was found to be significantly higher than that in normal 
ovaries [86]. However, it was shown that the mtDNA content in the pathologically high-grade (poorly 
differentiated) ovarian cancer was lower than that of the low-grade (well differentiated) ovarian cancer 
[86]. These findings suggest that a decrease in the mtDNA content is associated with the progression 
of ovarian cancer. 
Recently, a study of 153 colorectal cancer patients revealed that mtDNA content in colorectal 
cancers was higher than that in the corresponding non-cancerous colon tissues [80]. However, the 
mtDNA content was decreased in colorectal cancers with higher TNM stages and poorer differentiation 
[80]. The decrease in mtDNA content was correlated with a lower expression level of mitochondrial 
transcription factor A (mtTFA) or β subunit of the mitochondrial ATP synthase (β-F1-ATPase). It was 
suggested that mitochondrial dysfunction is associated with poor prognosis of colorectal cancer [80]. 
In contrast, it was observed in head and neck cancers that mtDNA content was increased with 
histopathologic grade from normal, moderate, dysplasia, severe dysplasia to invasive tumors [84]. The 
increase in mtDNA content was thought to be a feedback mechanism that compensates for a decline in 
respiratory function. In addition, Jiang et al. [93] reported that the mtDNA content in saliva from 
patients with primary head and neck squamous cell carcinoma was significantly higher than that of 
controls, and that an increase in the mtDNA content was associated with advanced tumor stage [93]. 
Based on the clinicopathologic correlations with somatic mtDNA alterations of cancers, these 
mtDNA alterations can potentially be used as a molecular prognostic indicator of cancers. Their 
correlations with poorer prognosis suggest that somatic mtDNA alterations in cancers may contribute 
to tumor recurrence and drug resistance in the process of cancer progression. 
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4. Reduced content of mitochondrial respiratory enzyme complexes in cancers 
  
Simonnet et al. [94] reported that the contents of mitochondrial respiratory enzyme Complexes II, 
III, IV, and V in renal cell carcinoma were significantly lower than those in normal kidney tissues. In 
addition, the decrease in mitochondrial respiratory enzyme complexes was correlated with the 
aggressiveness of renal cell carcinoma, suggesting that a decrease in the OXPHOS capacity favors 
faster growth or increased invasiveness of cancers [94]. It was also found that the contents of the 
subunits of mitochondrial respiratory enzyme Complexes II and III were decreased in HCCs [40]. A 
concomitant reduction in the copy number of mtDNA and the content of mitochondrial respiratory 
enzymes was observed in HCCs, which suggests that the biogenesis of mitochondria may be repressed 
in HCCs. 
The protein level of β-F1-ATPase was reduced in carcinomas of human liver, kidney, colon, breast, 
stomach, squamous esophagus and lung, which suggests that alteration of the bioenergetic function of 
mitochondria is a hallmark of these types of cancers [83,95]. Moreover, a reduction in the protein level 
of β-F1-ATPase in colon cancers was significantly correlated with both the time of recurrence of the 
disease and the survival of the patients [83]. These observations have led us to suggest that the 
metastases and recurrence of cancers may be linked to the down-regulation of the mitochondrial 
OXPHOS system. 
 
5. mtDNA mutations/mitochondrial dysfunction in cancer formation/progression 
  
Because β-F1-ATPase expression is down-regulated frequently in many types of cancers [83,95], 
pathogenic mutations in ATP synthase subunit 6 gene (ATPase 6) of mtDNA has provided a model to 
evaluate the role of defective mitochondrial ATPase in tumorigenesis and progression of cancers [96]. 
Petros et al. [97] introduced a pathogenic T8993G mutation in the ATPase 6 gene of mtDNA into the 
PC3 prostate cancer cell line through cytoplasmic transfer. They found that the tumor generated by 
transplantation of the cybrid carrying T8993G mutation was much larger than that produced by the 
transplantation of wild-type (T8993T) cybrid into the nude mice. Moreover, the tumors bearing the 
T8993G mtDNA mutation generated significantly more ROS. This study further substantiated that 
mtDNA mutation increased tumor growth in the prostate cancer. 
Using similar cybrid transfer technique, Shidara et al. [98] constructed cybrids containing HeLa 
nucleus and the T8993G or T9176C mutation in the ATPase 6 gene of mtDNA. They found that the 
mtDNA mutations conferred an advantage in the early stage of tumor growth in nude mice. By 
transplanting a mixture (1:1) of mutant and wild type cybrids into the nude mice, they observed that 
the proportion of mutant mtDNA in the tumor was increased progressively, and eventually the mutant 
mtDNA entirely replace the wild-type mtDNA [98]. These findings provide an explanation of the 
observation that most of somatic mtDNA mutations in many tumors tend to become homoplasmic 
during progression. In addition, apoptosis was found to occur less frequently in the mutant cybrids in 
cultures as compared with wild-type cybrids, which suggests that the pathogenic mtDNA mutations Int. J. Mol. Sci. 2009, 10                 
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might promote the growth of tumors by preventing apoptosis [98]. The mutant mtDNA in cybrids also 
exhibited resistance to cisplatin-induced apoptosis [98]. These results suggest that pathogenic mtDNA 
mutations may contribute to the progression of cancers and tolerance against anticancer drugs. 
Enhanced resistance to anticancer drugs was also observed in cultured cancer cells upon depletion 
of mtDNA and in cancer cells with mitochondrial respiratory chain defects [99-104]. Park et al. [100] 
reported that mtDNA-depleted human SK-Hep1 hepatoma cells are resistant to ROS generated by 
menadione, paraquat, and doxorubicin treatments, respectively. They suggested that an adaptive 
increase in the expression of manganese superoxide dismutase (MnSOD) and other antioxidant 
enzymes renders cancer cells harboring mtDNA mutation to counteract oxidative stress or 
chemotherapeutic agents [100]. Li et al. [102] found that pretreatment of human hepatoma HepG2 
cells and non-small cell lung cancer H1299 cells with chloramphenicol, an inhibitor of mitochondrial 
translation, rendered the cells resistant to mitomycin-induced apoptosis. The chloramphenicol- induced 
mitochondrial stress was shown to increase the expression of p21 and cause resistance to apoptosis 
through the p21-dependent pathway [102]. Shin et al. [103] investigated human colon cancer cells with 
5-fluorouracil (5-FU) resistance and found that the 5-FU-resistant cells exhibited lower expression of 
the α subunit of ATP synthase and lower ATP synthase activity in the mitochondria of cancers. These 
findings suggest that down-regulation of ATP synthase in colorectal carcinomas may lead to 5-FU 
resistance. Moreover, Pelicano et al. [104] observed that mitochondrial respiration defects induced by 
mtDNA deletion or chemical inhibitors led to the activation of the Akt survival pathway through a 
NADH-mediated PTEN inactivation. The activation of the Akt pathway in cancer cells may contribute 
to the observed resistance to drugs. 
MtDNA has also been shown to determine the hormone dependence in prostate or breast cancer cell 
lines [105,106]. Higuchi et al. [105] reported that an androgen- independent cell line, established by 
inoculation of the androgen-dependent LNCaP cell line into castrated mice, had greatly reduced 
content of mtDNA and an accumulation of large-scale deletions of mtDNA. The depletion of mtDNA 
from androgen-dependent LNCaP cells resulted in a loss of androgen dependence [105]. These results 
suggest that mtDNA defects play an important role in the development of androgen independence, 
which may contribute to the progression of prostate cancer. Moreover, Naito and colleagues [106] 
established hydroxytamoxifen-resistant breast cancer cells by growing human breast cancer cells 
MCF-7 in the presence of hydroxytamoxifen. They found that the mtDNA content was significantly 
reduced in the hydroxytamoxifen-resistant breast cancer cells. The mtDNA-depleted MCF-7 cells were 
established by long-term treatment with ethidium bromide and were also shown to be resistant to 
hydroxytamoxifen and ICI182780, respectively [106]. They further demonstrated that depletion of 
mtDNA induced by hormone therapy or other independent insults could trigger a shift to acquired 
resistance to hormone therapy in breast cancers. 
In addition, the development of multidrug resistance (MDR) phenotype could be enhanced by 
mtDNA depletion [107,108]. Lee et al. [107] demonstrated that human HCT-8 colon cancer cells with 
decreased mtDNA content exhibited higher tolerance to doxorubicin or vincristine, and that mtDNA 
depletion induced an increase in the expression level of mRNA of multidrug resistance 1 (MDR1) gene Int. J. Mol. Sci. 2009, 10                 
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and its translated P-glycoprotein [107]. These results suggest that mtDNA depletion may induce drug 
resistance through up-regulation of MDR1 gene expression in cancer cells. Ferraresi et al. [108] 
reported that when compared to parental cells, mtDNA-depleted human osteosarcoma 143B cells are 
less sensitive to apoptotic drugs including staurosporine, doxorubicine, daunomycin, and quercetin, 
respectively. Moreover, it was suggested that an increase in the content of reduced form of glutathione 
and overexpression of P-glycoprotein in the mtDNA-depleted cells may contribute to drug  
resistance [108]. 
In contrast, the mtDNA content in head and neck cancers appeared to increase with histopathologic 
grade from normal, moderate, dysplasia, severe dysplasia to invasive tumors [84]. Mizumachi et al. 
[109] created docetaxel-resistant cells from human laryngeal cancer HEp2 cells and found that the 
docetaxel-resistant cells had higher mtDNA contents. They also showed that an increase in the mtDNA 
content could induce acquired docetaxel resistance in head and neck cancer cells, and that mtDNA 
plays an important role in developing docetaxel resistance through the reduction of ROS generation by 
regulating the function of Fo-ATPase [109].   
Human mtDNA mutations or mitochondrial dysfunction may contribute to tumor progression by 
enhancing the metastatic potential of cancer cells. Amuthan et al. [110] showed that partial depletion 
of mtDNA or treatment with mitochondrial specific inhibitors induced invasive phenotypes in 
non-invasive C2C12 myoblasts and human lung cancer A549 cells. It was also reported that OXPHOS 
dysfunction could modulate the invasive phenotype by transcriptional regulation of extracellular 
matrix-remodeling genes [111]. Using hybrid technology to replace the endogenous mtDNA in tumor 
cells, Ishikawa et al. [112] demonstrated that ROS-generating mtDNA mutation can enhance 
metastatic potential of tumor cells. It was also reported that mtDNA-depleted LNCaP and MCF-7 cells 
exhibited invasive phenotype by epithelial-mesenchymal transition during depletion of mtDNA [113]. 
Results from the above-mentioned studies support that mtDNA mutations or mitochondrial 
dysfunction in cancer cells may play an important role in tumorigenesis, development of drug 
resistance, and metastasis of cancers. However, it should be noted that in creating cybrids with an 
mtDNA mutation or in the depletion of mtDNA of some cancer cell lines, diminished tumorigenic 
phenotypes were observed. These include slow cell proliferation, loss of anchorage-independent 
growth and increased sensitivity to cytotoxic chemotherapy [114-117]. Mitochondrial dysfunction 
induced by mtDNA mutation (e.g., A8344G) or inhibitors of respiratory chain was shown to impair 
proliferation of some cancer cells [118]. The molecular mechanisms by which mtDNA alterations or 
mitochondrial OXPHOS impairment affect tumor formation and cancer progression warrant further 
investigation. 
 
6. Potential Roles of Mitochondria-to-Nucleus Signaling in Human Cancers 
 
The expression of nuclear genes can be modulated in response to changes in the mitochondrial 
respiratory function in human cells. Mitochondrial dysfunction may induce the activation of nuclear 
transcription factors in a response called “retrograde response” [119,120]. The mitochondria-to- Int. J. Mol. Sci. 2009, 10                 
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nucleus retrograde signaling pathways have been described in yeast and mammalian cells [119, 120]. 
In yeast, numerous studies have shown that a retrograde signaling pathway can act as a homeostatic or 
stress response mechanism to adjust metabolic activities according to the state of mitochondrial 
function [120]. The retrograde signaling in mammalian cells, also known as mitochondrial stress 
signaling, has been demonstrated in C2C12 skeletal myoblasts and in human lung carcinoma A549 
cells [121,122]. Partial depletion of mtDNA or treatment with inhibitors of mitochondrial respiratory 
chain resulted in elevated cytosolic free Ca
2+ and activation of different nuclear transcription factors, 
which in turn induced the expression of specific nuclear genes that are involved in the progression of 
cancers [110,122]. Moreover, the mitochondria-to-nucleus retrograde signaling could induce 
aggressive and invasive phenotypes and resistance to apoptosis [101,110]. 
On the other hand, mtDNA mutation-elicited respiratory chain deficiency could result in 
over-production of ROS. ROS-induced oxidative stress is involved in the expression and regulation of 
nuclear genes related to carcinogenesis [123]. Recent studies showed that a pathogenic point mutation 
in the ATPase 6 gene of mtDNA led to over-production of ROS and enhanced tumor growth [97, 98]. 
Moreover, it was demonstrated that ROS over-production caused by mtDNA mutation can increase the 
metastatic potential of tumor cells [112]. These observations support a mechanism by which ROS 
mediate mitochondria-to-nucleus retrograde signaling that contributes to cancer progression  
and metastasis. 
A host of mtDNA mutations and mitochondrial dysfunction have been observed in various human 
cancers. It has been shown that mitochondrial stress signaling in different types of human cells can 
modulate the expression of nuclear genes involved in carcinogenesis and cancer progression. 
Communication between mitochondria and the nucleus may play an important role in the regulation of 
initiation and progression of cancers. Therefore, mitochondria and mtDNA may be good targets for 
development of drugs for treatment of cancers with certain metabolic alterations. 
 
7. Metabolic Shift in Cancers 
 
Although Warburg reported more than seven decades ago that an increase in the utilization of 
glucose for energy production is one of the distinct biochemical features of cancer cells, this 
phenomenon was not fully appreciated until 1990’s. In the past two decades there has been reemerging 
interest in the investigation of the mechanisms by which mitochondrial dysfunction and mtDNA 
mutations get involved in the pathophysiology and progression of cancers [124]. 
Pedersen’s group found that tumors that exhibited the most pronounced “Warburg effect” had 
functional mitochondria with the capacity to make ATP, but the mitochondrial content was reduced in 
cancer cells resulting in a decrease of net oxygen consumption capacity [125]. They further 
demonstrated that mitochondria-bound form of hexokinase (hexokinase 2, HK-2) plays a pivotal role 
in the “Warburg effect” [126]. In addition, the binding of HK-2 to voltage-dependent anion channel 
(VDAC) in the outer mitochondrial membrane facilitated the increase of glucose metabolism [127] and Int. J. Mol. Sci. 2009, 10                 
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the inhibition of apoptosis [128,129] by allowing preferred access of HK-2 to ATP synthesized on the 
inner membrane of mitochondria.   
The other lines of studies showed that the hypoxia microenvironment of tumor cells and the 
hypoxia-inducible factor (HIF) could contribute to the increase of gene expression and activities of 
some glycolytic enzymes [130,131]. Recently, it was further demonstrated that HIF-1-mediated 
expression of pyruvate dehydrogenase (PDH) kinase, which phosphorylates and inhibits the activity of 
PDH, is involved in the down-regulation of mitochondrial respiration [132,133]. These findings 
suggest that the hypoxic microenvironment of tumor cells and the activation of HIF-1 are involved in 
the enhanced utilization of glucose for energy production and reduced mitochondrial respiration. 
It was reported that mutations in the genes encoding subunits of succinate dehydrogenase (SDH) 
and fumarate hydratase of the tricarboxylic acid (TCA) cycle were associated with pheochromocytoma, 
paraganglioma or renal cell carcinoma, and that SDH down-regulation was observed in gastric and 
colon carcinoma [134]. Recent evidence revealed that succinate, a TCA cycle metabolite, is 
accumulated due to SDH down-regulation and transmits an “oncogenic” signal from mitochondria to 
the cytosol [135]. Succinate may inhibit HIF-1α prolyl hydroxylase and lead to stabilization of 
HIF-1α under normoxic conditions. Thus, succinate can increase the expression of genes that facilitate 
glycolysis in cancer cells [134,135]. 
Several recent studies revealed that the products of some oncogenes (e.g., ras, src, c-myc, or akt) 
can up-regulate the gene expression and activities of some glycolytic enzymes [136-139].
 The p53 
protein was recently shown to regulate mitochondrial respiration [140] and glucose metabolism [141]. 
In addition, Dang et al. [142] have also systemically investigated the mechanism by which some 
oncogenes or tumor suppressor genes get involved in the modification of energy metabolism and 
confer a preference for glucose utilization on human cancers. They and other investigators showed that 
the tumors with greater metastatic potential tend to rely more on glycolysis for supply of energy. These 
findings are consistent with the observations that a wide spectrum of mtDNA alterations and mtDNA 
depletion occur in the pre-cancerous as well as cancerous tissues in patients with various types of 
cancers [26,29,35,39]. We believe that the decrease in mtDNA copy number and/or expression of 
genes involved in mitochondrial biogenesis will cause impairment in the mitochondrial OXPHOS 
system. It is easily rationalized that a decrease in mtDNA copy number may also lead to a low 
abundance and/or decreased activity of mitochondria in cancer tissues. Under such circumstances, the 
rapidly growing cancer cells will have to shift the energy supply from aerobic metabolism to 
glycolysis. This indeed happens in many cancers, especially in the highly metastatic cancers. We found 
a decrease in the mtDNA copy number and lower ROS-triggered damage to mtDNA in lung cancer 
tissues [143]. We suggest that the decrease in oxidative DNA damage might be the result of a decrease 
in the metabolic activity and less production of ROS in the mitochondria of cancer cells. The other 
reason is the increase of production of NADPH, the reducing equivalent for maintenance of the GSH 
pool, through the pentose phosphate pathway that is enhanced by increased utilization of glucose. The 
decrease in the copy number of mtDNA and oxidative DNA damage may indicate that cancer cells Int. J. Mol. Sci. 2009, 10                 
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shift their energy supply from aerobic metabolism in mitochondria to glycolysis in the cytosol. The 
molecular mechanism underlying this phenomenon is under intensive studies. 
 
8. Concluding Remarks 
 
In the past decade, we and many other groups of investigators have demonstrated that mtDNA 
mutations occur in both cancerous and non-cancerous tissues of patients with various cancers. The 
sequence variations in the D-loop region, especially the D310 variations, are the most abundant point 
mutations of mtDNA in human cancers. The 4977 bp deletion is the most common large-scale deletion 
of mtDNA that occurs and accumulates in human cancers. Thus, mtDNA instability is a molecular 
hallmark of many types of human cancers. It was demonstrated that somatic D310 variations and 
alteration of the mtDNA copy number are correlated with the clinicopathological features or prognosis 
of some types of human cancers. Besides, it was found that a heterplasmy-to- homoplasmy shift of 
mtDNA generally occurs in the process of tumor progression. This may be caused by clonal expansion 
of cancer cells bearing certain mtDNA mutation(s) during the carcinogenesis and progression of 
cancers from the viewpoint of the replication and segregation of mtDNA. These mtDNA mutations as 
a whole may result in mitochondrial dysfunction due to decreased expression of mtDNA-encoded 
polypeptides and compromised function of respiratory enzyme complexes. Under such conditions, the 
affected cells will shift the reliance of ATP supply from aerobic metabolism to glycolysis, even in the 
presence of ample supply of oxygen. The cancer cells with defective mitochondria (and mutated 
mtDNA) also produce larger amounts of ROS and are thus exposed to higher oxidative stress. The 
mitochondria with higher oxidative stress may utilize the so-called retrograde signaling pathways to 
modulate the expression of nuclear genes involved in glycolysis and mitochondrial respiration and 
OXPHOS. This scenario, termed Warburg effect, may explain the observed increase in glucose 
utilization and higher lactate production in the formation and progression of cancers. Therefore, 
development of drugs that target to mitochondria or mtDNA may improve treatment of some types of 
human cancers in the future. In addition, it was recently shown that transformation of human 
mesenchymal stem cells is associated with an increase of OXPHOS [144]. Bioenergetic changes 
during transformation of stem cells might be quite different from those occur during the transformation 
of somatic cells. This may suggest that the mechanisms involved in the transformation of stem cells 
are different from that involved in differentiated cells transformation. The roles of the bioenergetic 
alterations of mitochondria in different types of cancers and cancer stem cells warrant further 
investigation.  
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